A Novel Use for Drotrecogin Alfa (Activated): Successful Treatment of Septic Shock Associated with Coccidioidomycosis | Zendy

Nancy F. Crum | Zendy; Harold L. Groff | Zendy; Scott Parrish | Zendy; W. Steves Ring | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Novel Use for Drotrecogin Alfa (Activated): Successful Treatment of Septic Shock Associated with Coccidioidomycosis

Author(s) -

Nancy F. Crum,

Harold L. Groff,

Scott Parrish,

W. Steves Ring

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/425918

Subject(s) - drotrecogin alfa , medicine , septic shock , intensive care medicine , antifungal , shock (circulatory) , severe sepsis , sepsis , immunology , dermatology

We present 2 cases of septic shock associated with coccidioidomycosis that were successfully treated with drotrecogin alfa (activated) in combination with antifungal agents. The favorable outcomes, in light of the high mortality usually associated with this condition, suggest that drotrecogin alfa (activated) may be a valuable adjunct for treating septic shock due to endemic mycoses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research